Who is sponsoring NCT05089136?

NCT05089136 is sponsored by Centre Chirurgical Marie Lannelongue.

What drugs are being tested in NCT05089136?

Interventions in NCT05089136: transcatheter paravalvular leak closure.

What condition does NCT05089136 study?

NCT05089136 studies Valvular Heart Disease, Valve Disease, Heart.

Is NCT05089136 still recruiting?

NCT05089136 is currently status unknown. Last updated 19 November 2021.

Last reviewed 2021-11-19 · How we verify

NCT05089136: FFPP1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcatheter Para-Valvular Leak Closure: An International Prospective Multicentre Registry

Status unknown Last updated 19 November 2021

What this trial tests

trial testing transcatheter paravalvular leak closure in Valvular Heart Disease in 213 participants. Status unknown.

Timeline

1 January 2017

Primary endpoint
31 December 2019

31 December 2021

Quick facts

Lead sponsor	Centre Chirurgical Marie Lannelongue
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	213
Start date	1 January 2017
Primary completion	31 December 2019
Estimated completion	31 December 2021

Drugs / interventions tested

transcatheter paravalvular leak closure

Conditions studied

Valvular Heart Disease — all drugs for Valvular Heart Disease →
Valve Disease, Heart — all drugs for Valve Disease, Heart →

Sponsor

Centre Chirurgical Marie Lannelongue — full company profile →

Who can join

Adults 18 to 100, any sex, with Valvular Heart Disease or Valve Disease, Heart. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prosthetic paravalvular leaks (PVL) leading to heart failure and/or haemolysis can be treated by interventional cardiology or open-heart surgery. Predictors of clinical success of transcatheter closure remains little known and should be identified to help choose between these two options.Patient selection criteria for the best option are needed. The investigators aimed to identify predictors of clinical success after transcatheter PVL closure. Consecutive patients referred to 24 European centres for transcatheter PVL closure in 2017-2019 were included in a prospective registry (Fermeture de Fuite ParaProthétique, FFPP) and followed over 2 years

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Predictors of Clinical Success After Transcatheter Paravalvular Leak Closure: An International Prospective Multicenter Registry.
Hascoët S, Smolka G, Blanchard D, Kloëckner M, et al · · 2022 · cited 18× · PMID 36256693 · DOI 10.1161/circinterventions.122.012193
3D-Printing to Plan Complex Transcatheter Paravalvular Leaks Closure.
Ciobotaru V, Tadros VX, Batistella M, Maupas E, et al · · 2022 · cited 12× · PMID 36012997 · DOI 10.3390/jcm11164758
Procedural Tools and Technics for Transcatheter Paravalvular Leak Closure: Lessons from a Decade of Experience.
Hascoët S, Smolka G, Kilic T, Ibrahim R, et al · · 2022 · cited 7× · PMID 36614920 · DOI 10.3390/jcm12010119

Verify or expand the search:

Other trials of transcatheter paravalvular leak closure

Trials testing the same drug.

NCT05117359 — Transcatheter Para-Valvular Leak Closures · completed

Other recruiting trials for Valvular Heart Disease

Currently open trials in the same condition.

NCT07197736 — DELINEATE-Prospective · recruiting
NCT07042529 — Optimized Expansion of the Implanted Transcatheter Aortic Valve · NA · recruiting
NCT07065500 — Mechanism and Effect of Novel Metabolites on Valvular Heart Disease · recruiting
NCT07099417 — Screening of Valvular Heart Disease Using Single-channel Electrocardiogram · recruiting
NCT06386016 — Detection of Valvular Heart Disease Using Artificial Intelligence-based Stethoscope · recruiting

Other Centre Chirurgical Marie Lannelongue trials

Trials by the same sponsor.

NCT05865119 — OPTImal Treatment of Sinus VENOSUS Defect · NA · recruiting
NCT05692310 — Study of the Effectiveness of Central Line Placement Using an Ultraportable Ultrasound Device · NA · unknown
NCT05717296 — Evaluation of the Effectiveness of a Multimedia Information Site in Reducing Preoperative Anxiety in Vascular Surgery Pa · NA · unknown
NCT06186258 — Infective Endocarditis in Percutaneous Pulmonary Revalvulation: Comparison Between Melody and Sapien Valves · completed
NCT05125965 — Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05089136 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Chirurgical Marie Lannelongue
Last refreshed: 19 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05089136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing